Top

American Journal of Clinical Dermatology

Published in:

01-06-2010 | Review Article

Psoriatic Arthritis: A Dermatologist’s Perspective

Author: Robert Alan Snyder

Published in: American Journal of Clinical Dermatology | Special Issue 1/2010

Abstract

Psoriatic arthritis (PsA) is a common, destructive arthritis that may manifest in more than one-third of psoriasis patients. Dermatologists are in a unique position to diagnose PsA early, and to start prompt, effective treatment. Such early intervention with biological agents such as tumor necrosis factor alpha antagonists, which appear to hold particular promise in the long-term management of PsA, may significantly reduce morbidity, improve quality of life and substantially reduce the economic (patient and societal) burden of PsA.

Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851–64PubMedCrossRef

Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1–19PubMedCrossRef

Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.e1–573.e13CrossRef

Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–73PubMedCrossRef

Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581–7PubMedCrossRef

Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)–an analysis of 220 patients. Q J Med 1987; 62: 127–41PubMed

Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245–50PubMedCrossRef

Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–4PubMed

Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 1247–50PubMed

10.

Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868–72

11.

Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–72PubMedCrossRef

12.

Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712–21PubMed

13.

Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–89PubMedCrossRef

14.

Mease P, Gladman D, Ritchlin C, et al. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial [abstract P2865]. J Am Acad Dermatol 2006; 54 (Suppl. 1): AB214

15.

Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150–7PubMedCrossRef

16.

Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498–505PubMedCrossRef

17.

Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638–45PubMedCrossRef

18.

Kavanaugh A, Mease P, Krueger G, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL Study [abstract 671]. 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology; 2008 October 24–29, 2008; San Francisco, California, USA; 2008

19.

Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007; 11: 57–66PubMed

Title: Psoriatic Arthritis: A Dermatologist’s Perspective
Author: Robert Alan Snyder
Publication date: 01-06-2010
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue Special Issue 1/2010
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/1153416-S0-000000000-00000

At a glance: The STEP trials

Springer Medicine

Psoriatic Arthritis: A Dermatologist’s Perspective

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Onset of Lichen Planus During Treatment with Etanercept

The Role of Biological Agents in the Treatment of Nail Psoriasis

Managing Pediatric Patients with Psoriasis

Etanercept Therapy for Psoriasis in a Patient with Numerous Comorbidities

Nicolau Syndrome Following Etanercept Administration

Etanercept in a Patient with Severe Psoriasis and Latent Viral Hepatic Disease and Latent Tuberculosis